Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$actu](/topic/$actu)

### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$actu/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$actu/time-series/sentiment.tsv)  
**Current Value**: XXX%  
**Daily Average**: XX%  
**1 Week**: XX% no change  
**1 Month**: XX% -XX%  
**1-Year High**: XXX% on 2025-05-16  
**1-Year Low**: XX% on 2025-08-29  

**Most Supportive Themes**
- **Breakthrough Cancer Treatment:** (45%) Actuate Therapeutics is developing innovative cancer therapies, with elraglusib showing promising results in pancreatic cancer, potentially doubling survival rates and enhancing treatment response.
- **Partnerships and Collaborations:** (25%) Actuate Therapeutics has established key partnerships with institutions like Harvard Medical School and Mass General Brigham, bolstering its clinical and regulatory momentum.
  
**Most Critical Themes**
- **Public Offering and Price Decline:** (30%)  Actuate Therapeutics stock has declined following a public offering, creating negative sentiment among investors.
  
Network engagement breakdown:  
| Network | Positive | %  | Neutral | %   | Negative | %  |
| ------- | -------- | -  | ------- | -   | -------- | -  |
| X       | X        | X% | XX      | XX% | X        | X% |
|         |          |    |         |     |          |    |
| Total   | X        | X% | XX      | XX% | X        | X% |

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$actu

Sentiment: XXX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
1 Week: XX% no change
1 Month: XX% -XX%
1-Year High: XXX% on 2025-05-16
1-Year Low: XX% on 2025-08-29

Most Supportive Themes

  • Breakthrough Cancer Treatment: (45%) Actuate Therapeutics is developing innovative cancer therapies, with elraglusib showing promising results in pancreatic cancer, potentially doubling survival rates and enhancing treatment response.
  • Partnerships and Collaborations: (25%) Actuate Therapeutics has established key partnerships with institutions like Harvard Medical School and Mass General Brigham, bolstering its clinical and regulatory momentum.

Most Critical Themes

  • Public Offering and Price Decline: (30%) Actuate Therapeutics stock has declined following a public offering, creating negative sentiment among investors.

Network engagement breakdown:

Network Positive % Neutral % Negative %
X X X% XX XX% X X%
Total X X% XX XX% X X%
$actu Sentiment
/topic/$actu/sentiment